Crispr Therapeutics AG (CRSP) Expected to Announce Quarterly Sales of $2.10 Million

Wall Street brokerages expect that Crispr Therapeutics AG (NASDAQ:CRSP) will announce sales of $2.10 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Crispr Therapeutics’ earnings. The lowest sales estimate is $500,000.00 and the highest is $3.70 million. Crispr Therapeutics posted sales of $2.34 million during the same quarter last year, which suggests a negative year-over-year growth rate of 10.3%. The firm is scheduled to announce its next earnings results on Friday, March 9th.

On average, analysts expect that Crispr Therapeutics will report full-year sales of $2.10 million for the current financial year, with estimates ranging from $9.20 million to $12.70 million. For the next fiscal year, analysts expect that the company will post sales of $14.67 million per share, with estimates ranging from $2.00 million to $24.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Wednesday, November 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.60) by ($0.02). The company had revenue of $2.39 million for the quarter, compared to analysts’ expectations of $3.61 million. Crispr Therapeutics had a negative net margin of 466.58% and a negative return on equity of 38.42%. The firm’s revenue for the quarter was up 54.2% compared to the same quarter last year. During the same period in the prior year, the firm posted ($2.77) earnings per share.

Several research firms recently commented on CRSP. SunTrust Banks raised Crispr Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Piper Jaffray Companies reissued a “buy” rating and issued a $22.75 price objective (down from $39.00) on shares of Crispr Therapeutics in a research note on Wednesday, January 10th. BidaskClub raised Crispr Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday, January 4th. Oppenheimer reissued a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, December 21st. Finally, Cann reissued a “hold” rating on shares of Crispr Therapeutics in a research note on Sunday, December 10th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $22.81.

Shares of Crispr Therapeutics (NASDAQ CRSP) traded down $1.11 during mid-day trading on Thursday, hitting $38.17. The stock had a trading volume of 310,509 shares, compared to its average volume of 1,032,580. The firm has a market cap of $1,913.65, a P/E ratio of -27.76 and a beta of 4.64. Crispr Therapeutics has a twelve month low of $11.63 and a twelve month high of $45.00.

In other Crispr Therapeutics news, insider Tyler Dylan-Hyde sold 15,000 shares of the firm’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $18.90, for a total value of $283,500.00. Following the completion of the sale, the insider now directly owns 130,204 shares of the company’s stock, valued at approximately $2,460,855.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Thomas Woiwode sold 1,700 shares of the firm’s stock in a transaction on Friday, November 24th. The stock was sold at an average price of $20.21, for a total value of $34,357.00. Following the completion of the sale, the director now directly owns 8,218 shares of the company’s stock, valued at $166,085.78. The disclosure for this sale can be found here. Insiders sold a total of 2,234,504 shares of company stock valued at $44,388,553 over the last ninety days. Corporate insiders own 39.98% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN increased its stake in shares of Crispr Therapeutics by 459.7% in the 2nd quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock worth $128,000 after acquiring an additional 6,560 shares during the last quarter. Creative Planning acquired a new stake in shares of Crispr Therapeutics in the 4th quarter worth $243,000. Capital Investment Advisory Services LLC purchased a new position in shares of Crispr Therapeutics during the 3rd quarter worth $193,000. Ark Investment Management LLC purchased a new position in shares of Crispr Therapeutics during the 2nd quarter worth $206,000. Finally, Moloney Securities Asset Management LLC purchased a new position in shares of Crispr Therapeutics during the 3rd quarter worth $235,000. 21.89% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/01/crispr-therapeutics-ag-crsp-expected-to-announce-quarterly-sales-of-2-10-million.html.

About Crispr Therapeutics

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply